Clinical trial

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

NCT00052377 · National Cancer Institute (NCI), NIH · Terminated

Key facts

NCT number NCT00052377
Title Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
Official title A Phase II Open-Label Study Of Recombinant Human Interleukin-12 (NSC 672423) In Mycosis Fungoides (MF) Patients With Cross-Over To Phase I Evaluation Of Escalating Doses Of Interleukin-2 (NSC 373364) Administered With Interleukin-12
Lead sponsor National Cancer Institute (NCI), NIH
Status Terminated
Phase Phase 1/Phase 2
Study type Interventional
Conditions Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome
Intervention type Biological, Other
Interventions aldesleukin, recombinant interleukin-12, laboratory biomarker analysis
Enrollment 46
Start date Sep 1, 2002
Primary completion Jun 1, 2005
First posted Jan 27, 2003
Last update posted Jan 16, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies